You can now read 10 articles each month for free on

The Boston Globe


MGH, AstraZeneca partner to create new drug combos

Advances in genetic profiling have allowed doctors to match more of their cancer patients with treatments that will target their particular illnesses. But for some about one-third of cancer patients, there are no good matches, leaving them with only conventional chemotherapies and radiation.

Now Dr. Keith T. Flaherty, an oncologist, and his colleagues at Massachusetts General Hospital have developed a more sophisticated formula for analyzing tumors to find their vulnerabilities.

Loading comments...

You have reached the limit of 10 free articles a month

Stay informed with unlimited access to Boston’s trusted news source.

  • High-quality journalism from the region’s largest newsroom
  • Convenient access across all of your devices
  • Today’s Headlines daily newsletter
  • Subscriber-only access to exclusive offers, events, contests, eBooks, and more
  • Less than $1 a week